RxDoctor Payments Data

Geoffrey Groff, MD

Family Medicine · Houston, TXNPI 1730184995

Payments from drug & device makers

$8,988in general payments, 2019–2025

Across 591 payments — averaging $15.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$692
  • Amarin Pharma, Inc.$677
  • Merck$647
  • Boehringer Ingelheim$608
  • AstraZeneca$569
  • plus $5K from 46 others

What the payments were for

  • Food & beverage$8,982100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,988 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$98,091
Medicare patients
382
Services billed
2,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$43,986
OzempicSemaglutide46$43,965
EliquisApixaban26$28,060
XareltoRivaroxaban18$19,050
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$16,014
PaxlovidNirmatrelvir/Ritonavir30$4,148
SynthroidLevothyroxine Sodium57$3,998
Rosuvastatin Calcium153$2,704
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,616
Albuterol Sulfate HfaAlbuterol Sulfate106$2,510
Olmesartan Medoxomil69$2,254
Atorvastatin Calcium308$2,061
Metoprolol Succinate132$1,619
Omeprazole157$1,550
Clobetasol Propionate18$1,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$608$43,98637 claims
Novo NordiskOzempic$1,188$43,96546 claims
PfizerEliquis, Paxlovid$465$32,20956 claims
Johnson & JohnsonXarelto$208$19,05018 claims
GSKTrelegy Ellipta, Shingrix$262$18,63032 claims
AbbVieSynthroid$503$3,99857 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →